secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001558370-23-004458
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports FY2022 net loss $17.6M; cash $22.1M; GT-02287 on track for Phase 1 in H2 2023
--------------------------------------------------------------------------------

- Net loss $17.6M ($1.48/share) vs $13.9M ($1.37) in 2021; R&D spend $8.4M, G&A $9.5M.
- Cash and marketable securities $22.1M as of Dec 31, 2022; runway expected into Q2 2024.
- GT-02287 IND-enabling studies completed H1 2023; Phase 1 dossier submission by mid-2023; Australian trial in H2 2023.
- Awarded €1.2M non-dilutive grant for Alpha-1 Antitrypsin Deficiency research program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/0001558370-23-004458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/ganx-20230323x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer